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and migrate from the media to the intima of the vessel
wall, which leads to the subsequent development of
atherosclerotic plaque and intimal hyperplasia.8,9
Structurally, TSP-1 consists of three identical chains,
and each chain contains six domains (Fig 1) that confer the
different functions associated with TSP-1.1,4,10 The actions
of the domains vary by cell type and species depending on
the extracellular matrix content and the receptors present
on the cell surface.11 The NH2 domain contains the
heparin-binding region1 and has been associated with
platelet aggregation12 and cell adhesion.13 The procolla-
gen homology (PCH) domain is where the three individ-
ual chains are linked by disulfide bonds.1,14 The three type
1 repeats (T1) have been implicated in cell attachment,
angiogenesis modulation, and chemotaxis and haptotaxis
in certain cell types (eg, skeletal myoblasts).13,15-18 There
are three type 2 repeats (T2), the functions of which have
not yet been elucidated. The seven type 3 repeats (T3),
with the last repeat containing the RGD sequence, have
been associated with calcium binding, cell adhesion, and
cell spreading13,18,19; a role in VSMC chemotaxis has also
been suggested.7 Finally, the C-terminal (COOH) domain
has been associated with cell attachment, platelet aggrega-
tion, and VSMC migration.13,20-22
TSP-1 is the major component of platelet α-granules,
released at the time of activation, along with platelet-
derived growth factor (PDGF) and other vasoactive pro-
teins.23 It has been noted by multiple sources that both
TSP-1 and PDGF contribute to VSMC chemotaxis.8,22
During the process of purification of TSP-1 from human
Thrombospondin-1 (TSP-1), a 420-kd matricellular
protein composed of three identical chains linked by disul-
fide bonds near the N-terminal (NH2),1,2 is virtually
absent in normal blood vessels. After acute arterial injury,
however, TSP-1 appears to act as an acute phase reactant,
as noted by a transient marked local increase at the site of
vessel injury.3-5 Although multiple functions have been
ascribed to TSP-1, including adhesion, proliferation, and
migration of many cell types,4,6,7 our research focuses on
TSP-1’s role in vascular smooth muscle cell (VSMC)
chemotaxis. Chemotaxis is the directed migration toward
a positive gradient of a soluble agonist in response to a
chemoattractant, such as TSP-1, and is an important
process in the development of vascular disease. After acute
arterial injury, VSMCs are exposed to chemoattractants
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Objective: Thrombospondin-1 (TSP-1), an acute-phase reactant implicated in vascular disease, is a 420-kd multifunc-
tional glycoprotein chemotactic for vascular smooth muscle cells (VSMCs). TSP-1 has six domains of repeating homolo-
gous amino acid sequences: N-terminal, procollagen homology, type 1 repeat, type 2 repeat, type 3 repeat/RGD (T3),
and C-terminal (COOH). The purpose of this experiment was to determine which domains of TSP-1 induce VSMC
chemotaxis.
Methods: A modified Boyden Chamber chemotaxis assay was used to assess VSMC migration. Serum-free medium, TSP-
1, or each of the fusion proteins (10 and 20 µg/mL) synthesized for the different domains were placed in the bottom
wells. Quiescent bovine aortic VSMCs (50,000) were placed in the top wells. After 4 hours at 37°C, migrated VSMCs
were recorded as cells per five fields (400×) and analyzed with the paired t test. To verify the fusion protein data, we
performed chemotaxis assays with antibodies to each of the domains (25 µg/mL) combined with TSP-1 (20 µg/mL)
in the bottom wells and VSMCs in the top wells.
Results: The COOH domain significantly stimulated VSMC chemotaxis (P = < .001). To a lesser extent, the N-termi-
nal and T3 domains also induced chemotaxis (P < .05). However, only the anti-COOH antibody (C6.7) and the
anti–integrin-associated protein portion of COOH antibody (D4.6) significantly inhibited TSP-1–induced VSMC
chemotaxis (by 85% and 92%, respectively). 
Conclusions: These results implicate the COOH domain as the portion of the TSP-1 molecule primarily responsible for
VSMC chemotaxis. This experiment suggests that future strategies in the prevention of VSMC migration, an initial step
in the development of vascular lesions, may involve selective inhibition of the COOH domain of TSP-1. (J Vasc Surg
2001;33:595-600.)
platelets, PDGF contamination is inevitable.24 The purpose
of our research was to determine the independent effect of
TSP-1 on VSMC chemotaxis and to determine which
domain of TSP-1 is responsible for inducing chemotaxis. To
avoid the confounding factor of PDGF contamination, we
studied the effects of fusion proteins, created to each of the
domains of TSP-1. Fusion proteins are created through the
recombinant production of amino acid sequences that cor-
respond to the different domains of TSP-1 and therefore,
do not involve the contamination issues associated with the
purification of platelets.17 This study was designed to deter-
mine which domains of TSP-1 are independently responsi-
ble for TSP-1–induced VSMC chemotaxis.
MATERIALS AND METHODS
General materials. Purified TSP-1 from human
platelets and fusion proteins to each of the six domains of
TSP-1 were prepared as described previously.12,17 Dulbecco
modified Eagle medium (DMEM) was obtained from
Sigma Chemical Co (St Louis, Mo). Dulbecco phosphate-
buffered saline, trypsin-ethylenediaminetetraacetic, and
fetal bovine serum were obtained from Gibco BRL Life
Technologies (Grand Island, NY). A 48-well microchemo-
taxis chamber and the poretics polycarbonate polyvinyl
pyrrolidone–free membranes (8-µm pores) were obtained
from Neuro Probe, Inc (Gaithersburg, Md). Enzyme-
linked immunosorbent assay (ELISA) kits were obtained
from R & D Systems (Minneapolis, Minn). The rabbit
polyclonal anti-TSP-1 immunoglobulin (Ig) G antibody
and the monoclonal anti–TSP-1 domain antibodies
(mAbs)—MBC 200.1 (anti-NH2 mouse IgG), A4.1 (anti-
T1 mouse IgM),15 A6.1 (anti-T2 mouse IgG),15,25
HB8432 (anti-T2 mouse IgG26), C6.7 (anti-COOH
mouse IgG),15,20,27 and D4.6 (anti–integrin-associated
protein [IAP] portion of COOH mouse IgG)15,25—were
obtained from Lab Vision Corp (Freemont, Calif).
Cell culture. Bovine aortic SMCs were isolated as
previously described28 and seeded in DMEM containing
10% fetal bovine serum in primary cell culture (2 × 104
cells per cm2). For all experiments, early passage (2–5)
cells were used. VSMCs in subconfluent monolayers were
growth arrested (48 hours) in serum-free medium (SFM)
before all experiments.
Chemotaxis assay. The 48-well modified Boyden
microchemotaxis chamber (NeuroProbe Inc, Gaithersburg,
Md) was used to assess migration.29 In the lower chamber,
30 µL of chemoattractant (eg, TSP-1) was placed. A poret-
ics membrane was applied, followed by the gasket and the
upper chamber. The cell suspension (50,000 VSMCs in 50
µL) was placed in the top chamber. Assays were conducted
over 4 hours at 37°C. The membrane was removed, fixed in
70% ethyl alcohol, stained with hematoxylin, and mounted
on a slide. Results were recorded as the total number of cells
migrated to the undersurface of the membrane for five high
power fields (400×).
To determine which domains of TSP-1 are involved in
VSMC chemotaxis, we placed SFM and unfused glu-
tathione S-transferase (10 µg/mL, negative control),
TSP-1 (10 and 20 µg/mL, positive control), and each of
the fusion proteins (10 and 20 µg/mL) in the bottom
wells of the chemotaxis chamber, and assays were per-
formed, as noted above. Chemotaxis assays were per-
formed with 30 µL of SFM (negative control), TSP-1 (20
µg/mL, positive control), or TSP-1 (20 µg/mL) com-
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Fig 1. TSP-1 is composed of three identical chains linked together by disulfide bonds at PCH domain. Each chain can be divided into
six domains of repeating homologous amino acid sequences: N-terminal (NH2), procollagen homology (PCH), type 1 repeat (T1), type
2 repeat (T2), type 3 repeat/RGD (T3), and C-terminal (COOH).
bined with the polyclonal anti–TSP-1 antibody or one of
the monoclonal antidomain antibodies (25 and 50
µg/mL) in the lower wells of the chamber to verify the
fusion protein data.
ELISA assays. The degree of PDGF contamination of
the TSP-1 and the fusion protein samples used in these
experiments was quantified with an ELISA on samples of
TSP-1 and fusion protein at a concentration of 20 µg/mL.
Statistical analysis. Each experiment was performed
in triplicate and repeated at least three times. The statisti-
cal analysis was performed with a paired t test (SigmaStat;
SPSS Science, Chicago, Ill), and a P value less than .05 was
considered significant.
RESULTS
Fig 2 summarizes the fusion protein data. The COOH
domain significantly induced VSMC chemotaxis (P =
<.0001 for 10 and 20 µg/mL). The chemotactic effect
seen by VSMCs in response to the fusion protein to 
the COOH domain is similar to that seen with purified
TSP-1 alone.29 Significant chemotaxis was also seen in
response to NH2 at both 10 and 20 µg/mL (P = .007 and
P = .001, respectively), but only at 20 µg/mL did T3-
induced VSMC chemotaxis reach statistical significance 
(P = .028). The chemotactic response elicited by NH2 at
a concentration of 10 µg/mL was not statistically differ-
ent from the response elicited by NH2 at a concentration
of 20 µg/mL (P = .465). The NH2 and T3 domains’
induction of chemotaxis was of a significantly lesser degree
than the COOH domain (at 10 µg/mL, P = .0021 for
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NH2 and P = < .0001 for T3; at 20 µg/mL P = .009 for
NH2 and P = .0004 for T3). Fusion proteins to the
remaining three domains had no significant effect on
VSMC chemotaxis.
The results of the fusion protein data were verified by
performing chemotaxis assays with mAbs directed against
the domains of TSP-1. As shown in Fig 3, only the anti-
COOH mAb, C6.7, and the anti-IAP portion of COOH
mAb, D4.6, significantly inhibited TSP-1–induced VSMC
chemotaxis to, respectively, 15% and 8% of TSP-1 alone
(in other words, these antibodies were responsible for an
85% and 92% inhibition of TSP-1–induced VSMC chemo-
taxis). The amount of inhibition by these two mAbs was
similar to the inhibition obtained by the polyclonal
anti–TSP-1 antibody, which resulted in a decrease in TSP-
1–induced chemotaxis to 13% of TSP-1 alone (an 87%
inhibition of TSP-1–induced chemotaxis). The remaining
mAbs resulted in no significant inhibition of TSP-
1–induced VSMC chemotaxis.
When performing these experiments, we found that
the anti-T1 IgM mAb, A4.1, stimulated VSMC chemo-
taxis independent of TSP-1 (results not shown).
Chemotaxis in response to mAb A4.1 combined with
TSP-1 was 118% of control (P = .263) (Fig 3). We then
performed a chemotaxis assay with a generalized mouse
IgM and were unable to demonstrate IgM-induced
VSMC chemotaxis (results not shown).
An ELISA assay for PDGF was performed on the puri-
fied TSP-1 and the fusion proteins used in these experi-
ments. The amount of PDGF contamination of the
Fig 2. Fusion protein-induced VSMC chemotaxis. Fusion proteins to six domains of TSP-1 were tested for their ability to induce VSMC
chemotaxis. Figure shows representative experiment of fusion protein-induced VSMC chemotaxis. Fusion proteins (10 and 20 µg/mL)
are listed across x-axis. The y-axis shows number of cells migrating to undersurface of the membrane for each of the fusion proteins;
SFM was used as negative control. Three experiments were performed for each of the fusion proteins (n = 3). The C-terminal domain
(COOH) and N-terminal domain (NH2) induced VSMC chemotaxis to a significant degree at 10 and 20 µg/mL (COOH: P = < .0001
at both concentrations; NH2: P = .007 for 10 µg/mL and P = .001 for 20 µg/mL). The type 3 repeat domain (T3) also induced chemo-
taxis but to a much lesser degree than COOH or NH2, and only at 20 µg/mL did degree of VSMC chemotaxis reach statistical signif-
icance (P = .028). Fusion proteins to the remaining three domains had no effect on VSMC chemotaxis. PCH, Procollagen homology;
SFM, serum-free medium; T1, type 1 repeat; T2, type 2 repeat; TSP-1, thrombospondin-1.
purified TSP-1 sample used in these experiments was
0.015 ng/mL. The assay was unable to detect any PDGF
contamination of the fusion proteins.
DISCUSSION
TSP-1 is a matricellular protein, because it has the
ability to bind both extracellular matrix proteins and cel-
lular receptors, and the effects of the molecule are the
result of these bindings.11 Multiple, often contradictory,
functions have been attributed to TSP-1, varying by both
cell type and species. This variability is thought to be due
to differences in the extracellular milieu and cell surface
receptors present in various different cell types.11 For
human and bovine VSMCs, TSP-1 has been shown to
induce chemotaxis.7,22,29 This process is important in the
migration of VSMCs from the media to the intima of the
vessel wall after acute arterial injury and in the subsequent
development of atherosclerotic plaque and intimal hyper-
plasia.30 Integrin receptors, specifically an αv-containing
integrin receptor, may be important in the mediation of
the interactions between TSP-1 and VSMCs and in the
resultant induction of migration.22
The effects that PDGF has on TSP-1–induced VSMC
chemotaxis have not yet been fully elucidated, although
previous data indicate that the effects are at least additive
and possibly synergistic.7,22 To determine the effect of
TSP-1 on VSMC chemotaxis independent of the con-
founding variable of PDGF, we performed chemotaxis
assays with fusion proteins to the different domains of
TSP-1. Both the fusion protein data and the antibody data
suggest that the COOH domain stimulates VSMC
chemotaxis. In the fusion protein experiments, the
COOH domain, at 20 µg/mL, resulted in a 7.4-fold
increase in the VSMC chemotactic response compared
with SFM (Fig 2), a level similar to that seen with purified
TSP-1. This suggests that the COOH domain has a pri-
mary role in promoting VSMC migration. Although there
have been other references made that the COOH domain
may be responsible for TSP-1–induced VSMC chemo-
taxis,22 the finding that the COOH domain may indepen-
dently stimulate VSMC migration is new. In addition, the
antibody experiments also indicate a primary role for
COOH in inducing VSMC chemotaxis, as noted by the
inhibition of TSP-1–induced chemotaxis in the presence
of the mAbs C6.7 (directed against COOH) and D4.6
(directed against the IAP portion of COOH).
Yabkowitz et al22 performed chemotaxis assays with
TSP-1; preincubated in the presence or absence of anti-
TSP mAbs C6.7, D4.6, A6.1, and A2.5 (anti-NH2)27,31;
and demonstrated inhibition of TSP-1–induced chemo-
taxis with mAb C6.7. In their experiments, no other mAb
tested inhibited migration. In our experiments, we
showed that C6.7 and D4.6 had an inhibitory effect on
chemotaxis (Fig 3). Because D4.6 specifically inhibits the
IAP portion of COOH, our studies indicate that the
COOH domain of TSP-1 interacts with an integrin recep-
tor on the surface of bovine aortic VSMCs and this bind-
ing results in a cascade of events that ultimately leads to
VSMC migration. Yabkowitz et al used bovine pulmonary
artery VSMCs for their experiments, and it is possible that
differences in VSMCs harvested from the pulmonary
artery versus those harvested from the aorta account for
the variability seen in the inhibition of TSP-1–induced
VSMC chemotaxis in the presence of the mAb D4.6.
Yabkowitz et al’s finding that mAb D4.6 does not inhibit
TSP-1–induced chemotaxis of pulmonary artery SMCs
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Fig 3. Inhibition of TSP-1-induced chemotaxis by anti–TSP-1 domain antibodies. mAbs directed against domains of TSP-1 were tested
for their ability to inhibit TSP-1–induced VSMC chemotaxis. Anti-COOH mAb (C6.7) and anti-IAP portion of COOH mAb (D4.6)
significantly inhibited TSP-1–induced VSMC chemotaxis to 15% and 8% of TSP-1 alone, respectively. In other words, these mAbs inhib-
ited TSP-1–induced VSMC chemotaxis by 85% and 92% (P < .05). The amount of inhibition by these two mAbs is similar to inhibition
obtained by polyclonal anti–TSP-1 antibody, which reduced TSP-1–induced chemotaxis to 13% of TSP-1 alone (ie, an 87% inhibition
of TSP-1–induced VSMC chemotaxis). Remaining mAbs resulted in no significant inhibition of TSP-1–induced VSMC chemotaxis.
Anti-T1 IgM mAb, however, was noted to stimulate VSMC chemotaxis to greater degree than control, 118% of TSP-1 alone. COOH,
C-terminal; NH2, N-terminal; T1, type 1 repeat; T2, type 2 repeat; TSP-1, thrombospondin-1.
suggests that TSP-1 acts through a different receptor
mechanism with these cells.
Previous studies support the functional importance of
IAP in cell migration and suggest that the effects seen with
TSP-1 are the result of its interactions with integrin recep-
tors on cell surfaces. Gao et al19 demonstrated that
melanoma cell spreading in response to TSP-1 is inhibited
by the anti-αvβ3 mAb LM609, indicating that TSP-1 asso-
ciation with integrin is important in the potentiation of
cell spreading. Wang and Frazier32 were able to partially
inhibit the binding of cells to 4N1K (a peptide from the
IAP-binding portion of the COOH cell-binding domain
of TSP-1) with the anti-IAP mAb 1F7, suggesting that
IAP may be partially responsible for TSP-1’s effect on
VSMCs. In addition, they were able to demonstrate that
4N1K is a potent VSMC chemotactic agent, and the mAb
P4C10 (directed against the β1 integrin subunit) was
capable of completely inhibiting 4N1K-induced VSMC
chemotaxis, indicating a role for the α2β1 integrin in aor-
tic VSMC chemotaxis.32 Stouffer et al33 showed that
cotreatment of human aortic VSMCs with TSP-1 and
mAb 7E3 (directed against the β3 integrin subunit) par-
tially inhibited TSP-1–induced VSMC proliferation, sug-
gesting that integrin activation by TSP-1 is important for
induction of VSMC proliferation. Further research to
define the role of IAP interactions with integrin receptors
in promotion of VSMC chemotaxis is still required.
Another domain that induced chemotaxis was the
NH2 domain. This may indicate that the NH2 domain is
also involved in VSMC chemotaxis, but in perhaps a sec-
ondary role, because the degree of chemotaxis is much less
than that observed for COOH (a 3.0-fold increase for
NH2 vs a 7.4-fold increase for COOH at 20 µg/mL).
There was also a significant degree of T3-induced VSMC
chemotaxis when we used the higher concentration (20
µg/mL) of T3. Previously, there has been speculation that
the T3 domain had a role in chemotaxis.7,18 From our
data, it would appear that the T3 domain has a relatively
minor role in the stimulation of VSMC chemotaxis (1.8-
fold > SFM). Lawler et al18 showed that the RGD
sequence, contained in the last T3 repeat, has an interac-
tion with the αvβ3 integrin receptor on human endothelial
cells and VSMCs, and they proposed that this interaction
is important for cell attachment to TSP-1.18 It is possible
that the T3 domain and the COOH domain work
together in the induction of chemotaxis in VSMCs.2,18
Further research needs to be performed to more fully
define the role of the T3 domain in VSMC chemotaxis,
including an assay to evaluate the chemotactic response to
a fusion protein created to a combination of the T3 and
COOH domains.
In conclusion, this study indicates that TSP-1 has an
effect on VSMC chemotaxis independent of PDGF. The
COOH domain is the principal domain of TSP-1 to
induce VSMC chemotaxis. In addition, the NH2 and T3
domains may also function in TSP-1–induced chemotaxis.
Consistent with the fusion protein data, antibodies
directed against the different domains of TSP-1 have
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shown that the anti-COOH mAb, C6.7, and the anti-IAP
portion of COOH mAb, D4.6, inhibited TSP-1–induced
VSMC chemotaxis to the same degree as the polyclonal
anti–TSP-1 antibody. This independent effect of the
COOH domain, which is similar to the effect of TSP-1
alone on chemotaxis, shows that this TSP-1 fragment war-
rants further study. Our findings suggest that selective
inhibition of the COOH domain of TSP-1 may be a help-
ful adjunct in the prevention of VSMC migration, a
process associated with the development of arterial lesions.
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